Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, Kristen E., Sammons, Morgan A., Odorizzi, Pamela M., Manne, Sasikanth, Godec, Jernej, Khan, Omar, Drake, Adam M., Chen, Zeyu +11 more·2016·Science
DOI 10.1126/science.aaf2807

Cited by (1,000)

Items 601–700 of 1,000

  1. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review
    Wu-Yan Xia, Wen Feng, Chenchen Zhang, Yujia Shen, Qin Zhang, Wen Juan Yu, Xu‐Wei Cai, Xiaolong Fu · 2020 · Translational Lung Cancer Research
  2. Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment
    Duojiao Wu · 2017 · Advances in experimental medicine and biology
  3. Metabolic Control of Memory T-Cell Generation and Stemness
    Jana L. Raynor, Nicole M. Chapman, Hongbo Chi · 2021 · Cold Spring Harbor Perspectives in Biology
  4. The adaptation of SARS-CoV-2 to humans
    Eduardo Tosta · 2021 · Memórias do Instituto Oswaldo Cruz
  5. Maladaptive consequences of inflammatory events shape individual immune identity
    Ariel Halper-Stromberg, Bana Jabrì · 2022 · Nature Immunology
  6. Trib1 regulates T cell differentiation during chronic infection by restraining the effector program
    Kelly Rome, Sarah J. Stein, Makoto Kurachi, Jelena Petrovic, Gregory W. Schwartz, Ethan A. Mack, Sacha Uljon, Winona W. Wu, Anne G. DeHart, Susan McClory et al. · 2020 · The Journal of Experimental Medicine
  7. Unravelling the heterogeneity and dynamic relationships of tumor-infiltrating T cells by single-cell RNA sequencing analysis
    Xin Yu, Lei Zhang, Ashutosh Chaudhry, Aaron S. Rapaport, Wenjun Ouyang · 2020 · Journal of Leukocyte Biology
  8. Tuberculosis–Cancer Parallels in Immune Response Regulation
    Thomas E. Bickett, S. Karam · 2020 · International Journal of Molecular Sciences
  9. PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity
    Helen Parry, Alexander C. Dowell, Jianmin Zuo, Kriti Verma, Francesca A. M. Kinsella, Jusnara Begum, Wayne D. Croft, Archana Sharma‐Oates, Guy Pratt, Paul A. H. Moss · 2021 · PLoS Pathogens
  10. A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells
    Joshua R. Veatch, Naina Singhi, Shivani Srivastava, Julia L. Szeto, Brenda L. Jesernig, Sylvia M. Stull, Matthew Fitzgibbon, Megha Sarvothama, Sushma Yechan-Gunja, Scott E. James et al. · 2021 · Journal of Clinical Investigation
  11. Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function
    Kristy Ou, Dania Hamo, Anne S. Schulze, Andy Roemhild, Daniel Kaiser, Gilles Gasparoni, Abdulrahman Salhab, Ghazaleh Zarrinrad, Leila Amini, Stephan Schlickeiser et al. · 2021 · Frontiers in Cell and Developmental Biology
  12. MicroRNA-29a attenuates CD8 T cell exhaustion and induces memory-like CD8 T cells during chronic infection
    Erietta Stelekati, Zhangying Cai, Sasikanth Manne, Zeyu Chen, Jean‐Christophe Beltra, Lance Alec Buchness, Xuebing Leng, Svetlana Ristin, Kito Nzingha, Viktoriya Ekshyyan et al. · 2022 · Proceedings of the National Academy of Sciences
  13. Exhaustion of CD39-Expressing CD8+ T Cells in Crohn’s Disease Is Linked to Clinical Outcome
    Anna-Maria Globig, L Mayer, Maximilian Heeg, Geoffroy Andrieux, Manching Ku, Patricia Otto-Mora, Anna Veronika Hipp, Katharina Zoldan, Ajinkya Pattekar, Nisha Rana et al. · 2022 · Gastroenterology
  14. Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
    Pei Zhou, Yawen Hu, Xiaoyan Wang, Luxuan Shen, Xinghao Liao, Yajuan Zhu, Jiadong Yu, Fulei Zhao, Yi Zhou, Hengshui Shen et al. · 2022 · Frontiers in Immunology
  15. Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
    Maria Alvanou, Memnon Lysandrou, Panayota Christofi, Nikoletta Psatha, Alexandros Spyridonidis, Αναστασία Παπαδοπούλου, Evangelia Yannaki · 2023 · Cancers
  16. Regulatory Mechanisms and Reversal of CD8+T Cell Exhaustion: A Literature Review
    Wanwan Zhu, Yiming Li, Mingwei Han, Jian‐Li Jiang · 2023 · Biology
  17. Continuous Expression of Interferon Regulatory Factor 4 Sustains CD8 + T Cell Immunity against Tumor
    Anze Yu, Jinfei Fu, Zheng Qin Yin, Hui Min Yan, Xiang Xiao, Dawei Zou, Xiaolong Zhang, Xiongbing Zu, X.C. Li, Wenhao Chen · 2023 · Research
  18. Vaccine immunotherapy with ARNAX induces tumor‐specific memory T cells and durable anti‐tumor immunity in mouse models
    Yohei Takeda, Sumito Yoshida, Ken Takashima, Noriko Ishii‐Mugikura, Hiroaki Shime, Tsukasa Seya, Misako Matsumoto · 2018 · Cancer Science
  19. T cell–derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death
    Nicholas H. Chun, Rosalind L. Ang, Mark Chan, Robert L. Fairchild, William M. Baldwin, Julian K. Horwitz, Jesse D. Gelles, Jerry E. Chipuk, Michelle A. Kelliher, Vasile I. Pavlov et al. · 2021 · JCI Insight
  20. Stem-like CD8+ T cells in cancer
    Chelsea Steiner, Nathan Denlinger, Xiaopei Huang, Yiping Yang · 2024 · Frontiers in Immunology
  21. Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
    Lingrong Hu, Chengliang Sun, Kai Yuan, Peng Yang · 2024 · Drug Discovery Today
  22. Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1+CD8+ and CD8+ T cells as predictive of response to neoadjuvant chemotherapy in breast cancer
    Hongling Liang, Hongsheng Li, Zhi Xie, Tian‐en Jin, Yu Chen, Zhiyi Lv, Xiaojun Tan, Jia Li, Guodong Han, Weixing He et al. · 2020 · Thoracic Cancer
  23. Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
    Marc Roth, Satya Das · 2020 · Expert Review of Anticancer Therapy
  24. Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
    Siwen Hu‐Lieskovan, Gabriel G. Malouf, Ira Allen Jacobs, Jeffrey Chou, Li Liu, Melissa Lynne Johnson · 2021 · Future Oncology
  25. Epigenetic Regulation of Cancer Immune Cells
    Diego M. Avella Patino, Vijay Radhakrishnan, Kanve Nagaraj Suvilesh, Yariswamy Manjunath, Guangfu Li, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Wesley C. Warren, Jussuf T. Kaifi, Jonathan B. Mitchem · 2021 · Seminars in Cancer Biology
  26. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer
    Lorena Ostios-García, Julia Villamayor, Esther Garcia-Lorenzo, D. Viñal, Jaime Feliú · 2021 · World Journal of Gastroenterology
  27. JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia
    Jacob M. Rosenberg, Joshua M. Peters, Travis K. Hughes, Caleb A. Lareau, Leif S. Ludwig, Lucas R. Massoth, Christina Anne Austin-Tse, Heidi L. Rehm, Bryan D. Bryson, Yi‐Bin Chen et al. · 2022 · Med
  28. CAR T Cell Immunotherapy Beyond Haematological Malignancy
    Cedric Hupperetz, Sangjoon Lah, Hyojin Kim, Chan Hyuk Kim · 2022 · Immune Network
  29. CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy.
    Dandan Feng, Dong-Qing Pu, Jinlu Ren, Ming Liu, Zhen Zhang, Zhiyong Liu, Jing-Wei Li · 2024 · Biochimica et biophysica acta. Reviews on cancer
  30. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer
    Maria Angela Aznar, Charly Ryan Good, Julie S. Barber-Rotenberg, Sangya Agarwal, Wesley V. Wilson, Alex Watts, Zhen Zhang, Donna M. Gonzales, Greg Donahue, Wei-Ting Hwang et al. · 2025 · Cell Reports Medicine
  31. Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion
    Mumtaz Yaseen Balkhi · 2020 · OncoImmunology
  32. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential
    Ken Maes, Anna Mondino, Juan José Lasarte, Xabier Agirre, Karin Vanderkerken, Felipe Prósper, Karine Breckpot · 2021 · Frontiers in Immunology
  33. SMAD4, activated by the TCR-triggered MEK/ERK signaling pathway, critically regulates CD8 + T cell cytotoxic function
    Xinwei Liu, Jing Hao, Peng Wei, Xiaohong Zhao, Qiuyan Lan, Lu Ni, Yongzhen Chen, Xue Bai, Ling Ni, Chen Dong · 2022 · Science Advances
  34. New Immuno-oncology Targets and Resistance Mechanisms
    Molly C. Tokaz, Christina S. Baik, A. McGarry Houghton, Diane Tseng · 2022 · Current Treatment Options in Oncology
  35. Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)
    Xiaoran Ma, Jibiao Wu, Bin Wang, Cun Liu, Lijuan Liu, Changgang Sun · 2022 · International Journal of Oncology
  36. Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment
    Maja K. Blake, Patrick M. O’Connell, Yasser Ali Aldhamen · 2023 · Frontiers in Cell and Developmental Biology
  37. Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versus chronic infection
    Lauren K. Quezada, Wenhao Jin, Yi Chia Liu, Eleanor S. Kim, Zhaoren He, Cynthia S. Indralingam, Tiffani Tysl, Lara Labarta-Bajo, Ellen J. Wehrens, Yeara Jo et al. · 2023 · PLoS Biology
  38. Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site
    Munetomo Takahashi, Tsz Y. So, Vitalina Chamberlain-Evans, Robert Hughes, Juan Carlos Yam‐Puc, Katarzyna Kania, Michelle Ruhle, Tiffeney Mann, Martijn J. Schuijs, Paul G. Coupland et al. · 2024 · Science Immunology
  39. MicroRNA regulation of CD8+ T cell responses
    John D Gagnon, Karl Mark Ansel · 2019 · Non-coding RNA Investigation
  40. Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy
    S. D. Singh, Navneet Singh, Manoj Baranwal, Siddharth Sharma, Shilpa Devi, Sandeep Kumar · 2023 · 3 Biotech
  41. A Trinity Nano-Vaccine System with Spatiotemporal Immune Effect for the Adjuvant Cancer Therapy after Radiofrequency Ablation
    Minghui Li, Anna Jiang, Huize Han, Meifang Chen, Bing Wang, Yuxi Cheng, Hua Zhang, Xueqing Wang, Wenbing Dai, Wei Yang et al. · 2023 · ACS Nano
  42. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
    Yikan Sun, Eloy Yinwang, Shengdong Wang, Zenan Wang, Fangqian Wang, Yucheng Xue, Wenkan Zhang, Shenzhi Zhao, Haochen Mou, Shixin Chen et al. · 2024 · Molecular Cancer
  43. The prostacyclin receptor PTGIR is a NRF2-dependent regulator of CD8+ T cell exhaustion
    Michael S. Dahabieh, Lisa M. DeCamp, Brandon M. Oswald, Susan M. Kitchen-Goosen, Zhen Fang Fu, Matthew Vos, Shelby E. Compton, Joseph Longo, Nicole M Foy, Kelsey S. Williams et al. · 2025 · Nature Immunology
  44. Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
    Moira C. Graves, Giovana Cellimarchett, Belinda van Zyl, Denise Tang, Ricardo E. Vilain, André van der Westhuizen, Nikola A. Bowden · 2019 · Frontiers in Medicine
  45. Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
    Lena Gaissmaier, Petros Christopoulos · 2020 · Respiration
  46. Runx proteins and transcriptional mechanisms that govern memory CD8 T cell development
    Matthew E. Pipkin · 2021 · Immunological Reviews
  47. Gene Regulatory Circuits in Innate and Adaptive Immune Cells
    Ankita Saini, Hazem E. Ghoneim, Chan‐Wang Jerry Lio, Patrick L. Collins, Eugene M. Oltz · 2022 · Annual Review of Immunology
  48. Single‐cell RNA‐seq reveals a microenvironment and an exhaustion state of T/NK cells in acute myeloid leukemia
    Zhiyong Zhang, Cong Deng, Pei Zhu, Danlin Yao, Jinlong Shi, Tiansheng Zeng, Wenhui Huang, Zeyong Huang, Zhihua Wu, Junyi Li et al. · 2023 · Cancer Science
  49. Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
    Claudia Cerella, Mario A. Dicato, Marc F. Diederich · 2023 · Pharmacological Research
  50. Ablation of interferon regulatory factor 4 in T cells induces “memory” of transplant tolerance that is irreversible by immune checkpoint blockade
    Hedong Zhang, Jie Wu, Dawei Zou, Xiang Xiao, Hui Yan, X.C. Li, Wenhao Chen · 2018 · American Journal of Transplantation
  51. Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors
    Gengtian Zhang, Mengyao Bai, Hong Du, Yue Yuan, Yidan Wang, Weijing Fan, Huachao Zhu, Di Wu, Pengcheng He, Busheng Xue · 2025 · ImmunoTargets and Therapy
  52. T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
    Yu Pu Yang, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun · 2026 · Advanced Science
  53. Disrupting the Code: Epigenetic Dysregulation of Lymphocyte Function during Infectious Disease and Lymphoma Development
    Andrea Di Pietro, Kim L. Good‐Jacobson · 2018 · The Journal of Immunology
  54. Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
    Sarah Elizabeth Fenton, Jeffrey Alan Sosman, Sunandana Chandra · 2019 · Cancer Drug Resistance
  55. High versus low dose irradiation for tumor immune reprogramming
    María Ochoa de Olza, Jean Bourhis, Melita B. Irving, George Coukos, Fernanda Gabriela Herrera · 2020 · Current Opinion in Biotechnology
  56. Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
    Peter Lawrence Smith, Katarzyna Piadel, Angus George Dalgleish · 2021 · Vaccines
  57. Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
    Hyun Ae Jung, Sehhoon Park, Yoon‐La Choi, Se-Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Jong-Mu Sun · 2022 · Clinical Cancer Research
  58. Lipids for CD8+ TILs: Beneficial or harmful?
    Duojiao Wu, Yuwen Chen · 2022 · Frontiers in Immunology
  59. Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
    Óscar Lapuente-Santana, Federica Eduati · 2020 · Frontiers in Oncology
  60. Informatics for cancer immunotherapy
    Jeff Hammerbacher, Alexandra Snyder · 2017 · Annals of Oncology
  61. Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy
    Sunita Keshari, Alexander S. Shavkunov, Qi Miao, Akata Saha, Tomoyuki Minowa, Martina Molgora, Charmelle D. Williams, Mehdi Chaib, Anna M. Highsmith, Josue Estiven Pineda et al. · 2024 · Cell Reports
  62. Ginsenoside Rg3 activates the immune function of CD8+ T cells via circFOXP1-miR-4477a-PD-L1 axis to induce ferroptosis in gallbladder cancer
    Zhipeng Ye, Jianfeng Ding, Jie Huang, Hu Zhao, Fa Jin, Keren Wu · 2024 · Archives of Pharmacal Research
  63. An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti‐Solid Tumor Immunity
    Yuejun Yao, Mingfei Wu, Yanfang Wang, Ziyan Liao, Yinxian Yang, Yun Liu, Jiaqi Shi, Wei Wu, Xinwei Wei, Jianchang Xu et al. · 2024 · Advanced Materials
  64. Getting the right combination to break the epigenetic code
    Seda Serra Tolu, Aaron D. Viny, Jennifer Effie Amengual, Barbara Pro, Susan Elaine Bates · 2024 · Nature Reviews Clinical Oncology
  65. Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
    Yu Liang, Wo‐Ming Chen, Youming Zhang, Lei Li · 2026 · Signal Transduction and Targeted Therapy
  66. The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment
    Isacco Ferrarini, Antonella Rigo, Carlo Visco, Mauro Krampera, Fabrizio Vinante · 2020 · Cancers
  67. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses
    Raquel Furtado, Laurent Chorro, Natalie Zimmerman, Erik Guillen, Emily Spaulding, Shu Shien Chin, Johanna Patricia Daily, Gregoire S. Lauvau · 2021 · Frontiers in Immunology
  68. Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells
    Sara Alavi, Abdullah Al Emran, Hsin‐Yi Tseng, Jessamy C. Tiffen, Helen Marie McGuire, Peter Hersey · 2022 · Cancers
  69. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
    Quanying Tang, Shikang Zhao, Ning Zhou, Jinling He, Lingling Zu, Tingwen Liu, Zuoqing Song, Jun Chen, Ling Peng, Song Xu · 2023 · International Journal of Oncology
  70. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment
    Hong Luo, Wenxiang Wang, Jia Mai, Rutie Yin, Xuyu Cai, Qintong Li · 2023 · Frontiers in Immunology
  71. Development of circulating CD4+ T‐cell memory
    Megan S. F. Soon, Jessica A. Engel, Hyun J Lee, Ashraful Haque · 2019 · Immunology and Cell Biology
  72. H3K4me3 mediates the NF-κB p50 homodimer binding to thepdcd1promoter to activate PD-1 transcription in T cells
    Priscilla S. Redd, Chunwan Lu, John David Klement, Mohammed L. Ibrahim, Gang Zhou, Takumi Kumai, Esteban Celis, Kebin Liu · 2018 · OncoImmunology
  73. Overcoming Resistance Mechanisms to Melanoma Immunotherapy
    David X. Zheng, David J. Bozym, Giuseppe Tarantino, Ryan Joseph Sullivan, David Liu, Russell William Jenkins · 2024 · American Journal of Clinical Dermatology
  74. Immune microenvironment of tumor-draining lymph nodes: insights for immunotherapy
    Jiahuan Wei, Daozhang Li, Haixia Long, Mei Han · 2025 · Frontiers in Immunology
  75. NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21WAF1/CIP1 overexpression, which is reversed by metformin
    Mark Williams, Xinhui Liu, Yueqi Zhang, Jake J. Reske, Devika Bahal, Trevor G. Gohl, Daniel P. Hollern, Elliot Ensink, Matti Kiupel, Rongcheng Luo et al. · 2020 · Oncogene
  76. Viral Hepatitides, Inflammation and Tumour Microenvironment
    Eleonora Timperi, Vincenzo Barnaba · 2020 · Advances in experimental medicine and biology
  77. Cancer systems immunology
    Nathan Edward Reticker-Flynn, Edgar G. Engleman · 2020 · eLife
  78. Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview
    João Calmeiro, Mylène A. Carrascal, Adriana Ramos Tavares, Daniel Alexandre Ferreira, Célia M. F. Gomes, Maria Teresa Cruz, Amílcar C. Falcão, Bruno Miguel Neves · 2020 · Pharmacological Research
  79. Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
    Fengkun Lu, Lei Hou, Sizhen Wang, Yingjie Yu, Yunchang Zhang, Linhong Sun, Chen Wang, Zhiqiang Ma, Feng Yang · 2021 · Drug Delivery
  80. Modulation of T cell function and survival by the tumor microenvironment
    Nikita Lavanya Mani, Dathan Andrews, Rebecca C. Obeng · 2023 · Frontiers in Cell and Developmental Biology
  81. Stem‐like T cells in cancer and autoimmunity
    Alexandra Schnell · 2024 · Immunological Reviews
  82. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1 low HCV-Specific CD8 + Cell Reactivity
    Elia Moreno Cubero, Dolores Subirá, Eduardo Sanz‐de‐Villalobos, Trinidad Parra-Cid, Antonio Madejón, Joaquín Miquel, Antonio Olveira, Alejandro González Praetorius, Javier García‐Samaniego, Juan Ramon Larrubia · 2017 · Journal of Virology
  83. Towards multiscale modeling of the CD8+T cell response to viral infections
    Subhasish Baral, Rubesh Raja, Pramita Sen, Narendra M. Dixit · 2019 · WIREs Systems Biology and Medicine
  84. Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells
    Zhang Fang, Xinyi Ding, Hao Huang, Hong-Wei Jiang, Jing-Ting Jiang, Xiao Zheng · 2024 · Cancer Biology and Medicine
  85. Tissue-resident exhausted and memory CD8+ T cells have distinct ontogeny, function and roles in disease
    Simone L. Park, Mark M. Painter, Sasikanth Manne, Víctor Alcalde, Maura McLaughlin, Matthew A. Sullivan, Divij Mathew, Leonel Torres, Yinghui Huang, David B. Reeg et al. · 2025 · Nature Immunology
  86. Structure of PD1 and its mechanism in the treatment of autoimmune diseases
    Mahdi Rezayi, Arezoo Hosseini · 2023 · Cell Biochemistry and Function
  87. Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
    Apoorvi Chaudhri, Gregory A. Lizee, Patrick Hwu, Kunal Rai · 2024 · Cancer Research
  88. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
    Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yunkai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David A. Flowers et al. · 2024 · Cancer Research
  89. Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure
    Selena Viganó, Sara Bobisse, George Coukos, Matthieu Perreau, Alexandre Harari · 2020 · Frontiers in Immunology
  90. Advanced Melanoma
    Alexandra M. Haugh, April K.S. Salama, Douglas Buckner Johnson · 2020 · Hematology/Oncology Clinics of North America
  91. Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer
    Chunlong Zhang, Qi Sheng, Xue Zhang, Kang Xu, Xiaoyan Jin, Weiwei Zhou, Mengying Zhang, Dezhong Lv, Changbo Yang, Yongsheng Li et al. · 2023 · iScience
  92. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma
    J. Xiong, Shu Cheng, Xiao Gao, Shan-He Yu, Yu-Ting Dai, Xin-Yun Huang, H. Zhong, Chao-Fu Wang, H. Yi, Hao Zhang et al. · 2024 · Signal Transduction and Targeted Therapy
  93. Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
    Xin Yan, Yongtian Zhao, Yang Liu, Qingming Yang, Liang Dong, Zhiqiang Wu, Jing Nie, Deyun Chen, Miaomiao Bai, Dongdong Ti et al. · 2020 · Frontiers in Oncology
  94. Immunological exhaustion: How to make a disparate concept operational?
    Hannah Kaminski, Maël Lemoine, Thomas Pradeu · 2021 · PLoS Pathogens
  95. New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy
    Nathaniel P. Oberholtzer, Kristen M. Quinn, Paramita Chakraborty, Shikhar Mehrotra · 2022 · Cells
  96. Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function
    Elsa Brunet‐Ratnasingham, Antigoni Morou, Mathieu Dubé, Julia Niessl, Amy E. Baxter, Olivier Tastet, Nathalie Brassard, Gloria-Gabrielle Ortega-Delgado, Roxanne Charlebois, Gordon James Freeman et al. · 2022 · EBioMedicine
  97. Cellular milieu in clear cell renal cell carcinoma
    Arti M. Raghubar, Matthew J. Roberts, Simon Wood, Helen Grania Healy, Andrew J. Kassianos, Andrew John Mallett · 2022 · Frontiers in Oncology
  98. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers
    Dong Yeul Lee, Talha Salahuddin, Jabed Iqbal · 2023 · Current Oncology
  99. Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment
    Ji Hyung Hong, In Sook Woo · 2023 · Cancer Letters
  100. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
    Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara et al. · 2023 · Cancer Medicine